Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2014

01-06-2014 | Original Article

Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis

Authors: Nobuaki Shiraki, Ayumu Nakashima, Shigehiro Doi, Juan Jesús Carrero, Naoko Sugiya, Toshinori Ueno, Peter Stenvinkel, Nobuoki Kohno, Takao Masaki

Published in: Clinical and Experimental Nephrology | Issue 3/2014

Login to get access

Abstract

Background

Low serum testosterone levels have been recently linked to endothelial dysfunction, arterial stiffness, and worse outcomes in male hemodialysis patients. We tested the hypothesis that low serum testosterone levels are also associated with atherosclerosis risk factors in postmenopausal women undergoing hemodialysis.

Methods

We measured serum testosterone in 115 confirmed postmenopausal ethnically Japanese women undergoing hemodialysis with mean age of 68.1 ± 10.6 years and median dialysis vintage of 73 months. The severity of atherosclerosis was evaluated by carotid intima–media thickness (cIMT) and cardio–ankle vascular index (CAVI). In addition, we also included a control cohort of 32 age-matched postmenopausal women without chronic kidney disease.

Results

Serum testosterone was significantly lower in women undergoing hemodialysis than in age-matched controls. Women undergoing hemodialysis who had undetectable testosterone concentration presented higher cIMT and higher CAVI than women undergoing hemodialysis with testosterone concentration above detection limits (P < 0.05 for all). Multiple logistic regression analyses confirmed the independence of these associations.

Conclusion

Serum testosterone levels in postmenopausal women undergoing hemodialysis are abnormally low and associated with features of atherosclerosis.
Literature
1.
go back to reference Carrero JJ. Gender differences in chronic kidney disease: underpinnings and therapeutic implications. Kidney Blood Press Res. 2010;33:383–92.PubMedCrossRef Carrero JJ. Gender differences in chronic kidney disease: underpinnings and therapeutic implications. Kidney Blood Press Res. 2010;33:383–92.PubMedCrossRef
2.
go back to reference Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26:184–90.PubMedCrossRef Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26:184–90.PubMedCrossRef
3.
go back to reference Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant. 2012;27:4030–41.PubMedCrossRef Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant. 2012;27:4030–41.PubMedCrossRef
4.
go back to reference Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110:563–72.PubMedCrossRef Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110:563–72.PubMedCrossRef
6.
go back to reference Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 1996;125:1–13.PubMedCrossRef Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 1996;125:1–13.PubMedCrossRef
7.
go back to reference Shapiro J, Christiana J, Frishman WH. Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther. 1999;6:167–74.PubMedCrossRef Shapiro J, Christiana J, Frishman WH. Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther. 1999;6:167–74.PubMedCrossRef
8.
go back to reference Jones RD, Pugh PJ, Jones TH, et al. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol. 2003;138:733–44.PubMedCentralPubMedCrossRef Jones RD, Pugh PJ, Jones TH, et al. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol. 2003;138:733–44.PubMedCentralPubMedCrossRef
9.
go back to reference Foresta C, Caretta N, Lana A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91:4599–602.PubMedCrossRef Foresta C, Caretta N, Lana A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91:4599–602.PubMedCrossRef
10.
go back to reference Dalia S, Fortune K, Anat J, et al. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension. 1998;32:39–45. Dalia S, Fortune K, Anat J, et al. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension. 1998;32:39–45.
11.
go back to reference Carrero JJ, Bárány P, Yilmaz MI, et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012;27:709–15.PubMedCrossRef Carrero JJ, Bárány P, Yilmaz MI, et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012;27:709–15.PubMedCrossRef
12.
go back to reference Cigarran S, Pousa M, Castro MJ, et al. (2013) Endogenous testosterone, muscle strength and fat-free mass in men with chronic kidney disease. J Ren Nutr. Cigarran S, Pousa M, Castro MJ, et al. (2013) Endogenous testosterone, muscle strength and fat-free mass in men with chronic kidney disease. J Ren Nutr.
13.
go back to reference Yilmaz MI, Sonmez A, Qureshi AR, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1617–25.PubMedCrossRef Yilmaz MI, Sonmez A, Qureshi AR, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1617–25.PubMedCrossRef
14.
go back to reference Kyriazis J, Tzanakis I, Stylianu K, et al. Low serum testosterone, arterial stiffness and mortality in male hemodialysis patients. Nephrol Dial Transplant. 2011;26:2971–7.PubMedCrossRef Kyriazis J, Tzanakis I, Stylianu K, et al. Low serum testosterone, arterial stiffness and mortality in male hemodialysis patients. Nephrol Dial Transplant. 2011;26:2971–7.PubMedCrossRef
15.
go back to reference Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab. 2010;95:740–7.PubMedCentralPubMedCrossRef Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab. 2010;95:740–7.PubMedCentralPubMedCrossRef
16.
go back to reference Sievers C, Klotsche J, Pieper L, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol. 2010;163:699–708.PubMedCrossRef Sievers C, Klotsche J, Pieper L, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol. 2010;163:699–708.PubMedCrossRef
17.
go back to reference Creatsa M, Armeni E, Stamatelopoulos K, et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism. 2012;61:193–201.PubMedCrossRef Creatsa M, Armeni E, Stamatelopoulos K, et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism. 2012;61:193–201.PubMedCrossRef
18.
go back to reference Patel SM, Ratcliffe SJ, Reilly MP, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2009;94:4776–84.PubMedCentralPubMedCrossRef Patel SM, Ratcliffe SJ, Reilly MP, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2009;94:4776–84.PubMedCentralPubMedCrossRef
19.
go back to reference McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14:103–15.PubMedCrossRef McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14:103–15.PubMedCrossRef
20.
go back to reference Kramer HM, Curhan GC, Singh A, et al. Permanent cessation of menses and postmenopausal hormone use in dialysis-dependent women: the HELP study. Am J Kidney Dis. 2003;41:643–50.PubMedCrossRef Kramer HM, Curhan GC, Singh A, et al. Permanent cessation of menses and postmenopausal hormone use in dialysis-dependent women: the HELP study. Am J Kidney Dis. 2003;41:643–50.PubMedCrossRef
21.
go back to reference Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb. 1993;13:1404–11.PubMedCrossRef Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb. 1993;13:1404–11.PubMedCrossRef
22.
go back to reference Shirai K, Utino J, Otsuka K, et al. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101–7.PubMedCrossRef Shirai K, Utino J, Otsuka K, et al. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101–7.PubMedCrossRef
23.
go back to reference Zoungas S, Cameron JD, Kerr PG, et al. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis. 2007;50:622–30.PubMedCrossRef Zoungas S, Cameron JD, Kerr PG, et al. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD. Am J Kidney Dis. 2007;50:622–30.PubMedCrossRef
24.
go back to reference Shoji T, Maekawa K, Emoto M, et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis. 2010;210:145–9.PubMedCrossRef Shoji T, Maekawa K, Emoto M, et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis. 2010;210:145–9.PubMedCrossRef
25.
26.
go back to reference Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab. 2001;86:2437–45.PubMed Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab. 2001;86:2437–45.PubMed
27.
go back to reference Schmidt A, Luger A, Hörl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant. 2002;17:368–71.PubMedCrossRef Schmidt A, Luger A, Hörl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant. 2002;17:368–71.PubMedCrossRef
28.
go back to reference Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7:207–15.PubMedCentralPubMedCrossRef Carrero JJ, Kyriazis J, Sonmez A, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7:207–15.PubMedCentralPubMedCrossRef
29.
go back to reference Strippoli GF. Collaborative depression and sexual dysfunction (CDS) in hemodialysis working group. Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol. 2012;7:974–81.PubMedCentralPubMedCrossRef Strippoli GF. Collaborative depression and sexual dysfunction (CDS) in hemodialysis working group. Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol. 2012;7:974–81.PubMedCentralPubMedCrossRef
30.
go back to reference Hladunewich M, Hercz AE, Keunen J, et al. Pregnancy in end stage renal disease. Semin Dial. 2011;24:634–9.PubMedCrossRef Hladunewich M, Hercz AE, Keunen J, et al. Pregnancy in end stage renal disease. Semin Dial. 2011;24:634–9.PubMedCrossRef
31.
go back to reference Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002;155:437–45.PubMedCrossRef Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol. 2002;155:437–45.PubMedCrossRef
32.
go back to reference Montalcini T, Gorgone G, Gazzaruso C, et al. Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr Metab Cardiovasc Dis. 2007;17:705–11.PubMedCrossRef Montalcini T, Gorgone G, Gazzaruso C, et al. Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr Metab Cardiovasc Dis. 2007;17:705–11.PubMedCrossRef
33.
go back to reference Bernini GP, Sgro’ M, Barlascini CO, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab. 1999;84:2008–12.PubMedCrossRef Bernini GP, Sgro’ M, Barlascini CO, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab. 1999;84:2008–12.PubMedCrossRef
34.
go back to reference Yaron M, Greenman Y, Rosenfeld JB, et al. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol. 2009;160:839–46.PubMedCrossRef Yaron M, Greenman Y, Rosenfeld JB, et al. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol. 2009;160:839–46.PubMedCrossRef
35.
go back to reference Dockery F, Bulpitt CJ, Donaldson M, et al. The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc. 2003;51:1627–32.PubMedCrossRef Dockery F, Bulpitt CJ, Donaldson M, et al. The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc. 2003;51:1627–32.PubMedCrossRef
36.
go back to reference Hougaku H, Fleg JL, Najjar SS, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006;290:E234–42.PubMedCrossRef Hougaku H, Fleg JL, Najjar SS, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006;290:E234–42.PubMedCrossRef
37.
go back to reference Montalcini T, Gorgone G, Gazzaruso C, et al. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis. 2007;18:9–13.PubMedCrossRef Montalcini T, Gorgone G, Gazzaruso C, et al. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis. 2007;18:9–13.PubMedCrossRef
38.
go back to reference Izuhara M, Shioji K, Kadota S, et al. Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J. 2008;72:1762–7.PubMedCrossRef Izuhara M, Shioji K, Kadota S, et al. Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary arteriosclerosis. Circ J. 2008;72:1762–7.PubMedCrossRef
39.
go back to reference Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013;23:77–90.PubMedCrossRef Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013;23:77–90.PubMedCrossRef
40.
go back to reference Nettleship JE, Jones TH, Channer KS, et al. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427–34.PubMedCrossRef Nettleship JE, Jones TH, Channer KS, et al. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427–34.PubMedCrossRef
41.
go back to reference Braunstein GD, Johnson BD, Stanczyk FZ, et al. Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab. 2008;93:4268–75.PubMedCentralPubMedCrossRef Braunstein GD, Johnson BD, Stanczyk FZ, et al. Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab. 2008;93:4268–75.PubMedCentralPubMedCrossRef
42.
go back to reference Foresta C, Zuccarello D, De Toni L, et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf). 2008;68:284–9. Foresta C, Zuccarello D, De Toni L, et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf). 2008;68:284–9.
43.
go back to reference Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004;69:279–89.PubMedCrossRef Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids. 2004;69:279–89.PubMedCrossRef
44.
go back to reference Webb CM, Elkington AG, Kraidly MM, et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. 2008;101:618–24.PubMedCentralPubMedCrossRef Webb CM, Elkington AG, Kraidly MM, et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. 2008;101:618–24.PubMedCentralPubMedCrossRef
45.
go back to reference Malkin CJ, Jones RD, Jones TH, et al. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006;111:265–74.CrossRef Malkin CJ, Jones RD, Jones TH, et al. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006;111:265–74.CrossRef
46.
go back to reference Ros S, Carrero JJ. Endocrine alterations and cardiovascular risk in CKD: is there a link? Nefrologia. 2013;33:181–7.PubMed Ros S, Carrero JJ. Endocrine alterations and cardiovascular risk in CKD: is there a link? Nefrologia. 2013;33:181–7.PubMed
Metadata
Title
Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis
Authors
Nobuaki Shiraki
Ayumu Nakashima
Shigehiro Doi
Juan Jesús Carrero
Naoko Sugiya
Toshinori Ueno
Peter Stenvinkel
Nobuoki Kohno
Takao Masaki
Publication date
01-06-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0840-6

Other articles of this Issue 3/2014

Clinical and Experimental Nephrology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.